Semanteon Capital Management LP Takes $531,000 Position in Glaukos Co. (NYSE:GKOS)

Semanteon Capital Management LP purchased a new stake in shares of Glaukos Co. (NYSE:GKOS) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 6,686 shares of the medical instruments supplier’s stock, valued at approximately $531,000.

Several other institutional investors and hedge funds have also recently modified their holdings of GKOS. CWM LLC raised its stake in shares of Glaukos by 309.5% during the third quarter. CWM LLC now owns 1,384 shares of the medical instruments supplier’s stock valued at $104,000 after acquiring an additional 1,046 shares in the last quarter. Valeo Financial Advisors LLC raised its stake in shares of Glaukos by 57.4% during the third quarter. Valeo Financial Advisors LLC now owns 9,082 shares of the medical instruments supplier’s stock valued at $683,000 after acquiring an additional 3,312 shares in the last quarter. Harbor Capital Advisors Inc. raised its stake in shares of Glaukos by 29.0% during the third quarter. Harbor Capital Advisors Inc. now owns 20,384 shares of the medical instruments supplier’s stock valued at $1,534,000 after acquiring an additional 4,581 shares in the last quarter. Commonwealth Equity Services LLC increased its holdings in Glaukos by 20.7% during the third quarter. Commonwealth Equity Services LLC now owns 5,582 shares of the medical instruments supplier’s stock valued at $420,000 after buying an additional 959 shares during the period. Finally, Xponance Inc. purchased a new position in Glaukos during the third quarter valued at approximately $208,000. Institutional investors own 99.04% of the company’s stock.

Glaukos Stock Down 0.6 %

NYSE GKOS traded down $0.63 on Friday, hitting $99.48. The stock had a trading volume of 288,682 shares, compared to its average volume of 655,646. Glaukos Co. has a 52-week low of $45.38 and a 52-week high of $103.66. The stock has a market cap of $4.99 billion, a price-to-earnings ratio of -35.78 and a beta of 1.08. The company has a debt-to-equity ratio of 0.77, a current ratio of 5.34 and a quick ratio of 4.78. The business’s fifty day moving average price is $92.29 and its 200 day moving average price is $81.55.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, February 21st. The medical instruments supplier reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.07). Glaukos had a negative return on equity of 22.67% and a negative net margin of 42.79%. The firm had revenue of $82.40 million during the quarter, compared to analysts’ expectations of $81.00 million. During the same quarter in the previous year, the business earned ($0.53) earnings per share. The company’s revenue for the quarter was up 15.7% compared to the same quarter last year. Equities research analysts anticipate that Glaukos Co. will post -2.18 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on GKOS. Citigroup lifted their price objective on shares of Glaukos from $107.00 to $120.00 and gave the company a “buy” rating in a report on Monday, March 25th. StockNews.com lowered shares of Glaukos from a “hold” rating to a “sell” rating in a report on Tuesday, February 27th. Stifel Nicolaus reissued a “buy” rating and set a $110.00 price objective on shares of Glaukos in a report on Wednesday, April 3rd. Mizuho lifted their price objective on shares of Glaukos from $85.00 to $100.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. Finally, Wells Fargo & Company lifted their price objective on shares of Glaukos from $83.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $99.80.

Insider Buying and Selling

In other Glaukos news, COO Joseph E. Gilliam sold 59,801 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $100.47, for a total value of $6,008,206.47. Following the sale, the chief operating officer now directly owns 101,845 shares of the company’s stock, valued at $10,232,367.15. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Glaukos news, COO Joseph E. Gilliam sold 59,801 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $100.47, for a total value of $6,008,206.47. Following the sale, the chief operating officer now directly owns 101,845 shares of the company’s stock, valued at $10,232,367.15. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Gilbert H. Kliman sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $88.25, for a total value of $441,250.00. Following the completion of the sale, the director now directly owns 30,620 shares in the company, valued at $2,702,215. The disclosure for this sale can be found here. Insiders have sold a total of 242,357 shares of company stock valued at $22,857,372 over the last ninety days. Company insiders own 6.40% of the company’s stock.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.